Ironwood Pharmaceuticals Inc (IRWD)

IRWD (NASDAQ:Drugs) EQUITY
$15.04
neg -0.63
-4.02%
Today's Range: 14.89 - 15.84 | IRWD Avg Daily Volume: 1,324,400
Last Update: 01/17/17 - 4:00 PM EST
Volume: 927,259
YTD Performance: 2.49%
Open: $15.20
Previous Close: $15.67
52 Week Range: $7.35 - $14.35
Oustanding Shares: 146,223,549
Market Cap: 2,291,323,013
6-Month Chart
TheStreet Ratings Grade for IRWD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 3
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.00 2.14
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -30.13
Price Earnings Comparisons:
IRWD Sector Avg. S&P 500
-30.13 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.06% 50.10% 26.37%
GROWTH 12 Mo 3 Yr CAGR
Revenue 95.70 0.00 0.00
Net Income 0.00 1.00 0.00
EPS 0.00 0.50 0.00
Earnings for IRWD:
EBITDA -0.09B
Revenue 0.15B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $-0.25 $-0.14 $-0.72 $-0.40
Number of Analysts 4 2 3 5
High Estimate $-0.19 $-0.10 $-0.66 $-0.29
Low Estimate $-0.30 $-0.18 $-0.77 $-0.75
Prior Year $-0.10 $-0.08 $-0.93 $-0.72
Growth Rate (Year over Year) -145.00% -75.00% 22.58% 45.00%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Twelve-month upside $260 (+33%) Twelve-month downside $175 (-10%) AGN has a significant pipeline and a potentially important near-term catalyst:  The company and its partner, Ironwood Pharmaceuticals (IRWD) , have just announced good results from a Phase 2b trial that investigated delayed-release versions of Linzess. Well-tolerated with no adverse events, this holds large potential. CR1 (ileum), in particular, could significantly improve on the strengths of Linzess. More than one third of the CR1 patients have reported pai

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.
I expect Allergan or another player to bid for SGYP soon.
Bullish
Feb 06, 2015 | 7:43 AM EST
IRWD was upgraded form Sell to Hold, Cantor Fitzgerald said. Company lacks negative near-term catalysts. $13.50 price target. 
Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The
Bearish
Nov 06, 2014 | 6:54 AM EST
IRWD was downgraded from Hold to Sell, Cantor Fitzgerald said. $10 price target. Valuation call, as the company will likely spend more ...
Bullish
Jul 24, 2013 | 7:51 AM EDT
IRWD was upgraded to Hold, Cantor Fitzgerald said. $10 price target. Linzess can continue to grow and the company is keeping a tight li...
Bullish
May 30, 2013 | 8:09 AM EDT
IRWD was upgraded from Underperform to Neutral, Wedbush said. $12 price target. Linzess prescriptions are growing.
The negative surprises indicate hidden weakness in a business, and the stocks are to be avoided.
Bearish
Apr 24, 2013 | 8:17 AM EDT
Shares of IRWD were downgraded to Underperform  from Neutral, said Wedbush. Cash burn is occurring much faster than expected given...

Columnist Conversations

Shares of PG area trading at new January highs this afternoon.  The stock is up over 1.75% and has been m...
Market slightly down across the board to start the holiday shortened trading week.  NASDAQ getting hit th...
This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both revenue and earnings. ...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Chipotle Mexican Grill...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.